In line with the ICB-resistant nature of the 4T1- and 66cl4-based model, anti-PD-1 monotherapy did not reduce disease progression by 5 w p.i. compared to untreated tumor-bearing mice, based on tumor volume measurements (Fig. 1B,C) and concomitant in vivo imaging (Fig. 1D–G). This evidence concerns the gene PDCD1 and neoplasm.